Patents Assigned to Universite de Montpellier
-
Publication number: 20200155504Abstract: The present invention relates to a composition comprising urolithin A, urolithin B, urolithin C, urolithin D, or a combination thereof, for the stimulation of insulin secretion, and to the use of a compound chosen among urolithin A, urolithin B, urolithin C, urolithin D, or a combination thereof, intended for the stimulation of insulin secretion. The present invention also relates to a composition comprising an effective amount of urolithin B, urolithin C, urolithin D, or a combination thereof, for the treatment or the prevention of diabetes mellitus, and in particular for the treatment or the prevention of type 2 diabetes, and to the use of a compound chosen among urolithin B, urolithin C, urolithin D, and a combination thereof, intended for the treatment or the prevention of diabetes mellitus, and in particular of type 2 diabetes.Type: ApplicationFiled: January 24, 2020Publication date: May 21, 2020Applicants: Centre National de la Recherche Scientifique, Universite de Montpellier, University of Parma, Ecole Nationale Superieure de ChimieInventors: Gerard Cros, Alan Crozier, Margherita Dall'asta, Daniele Del Rio, Richard Magous, Catherine Oiry
-
Patent number: 10654813Abstract: Compounds and pharmaceutically acceptable salts thereof that may be used to treat a disease, for example, Duchenne muscular dystrophy, AIDS, and progeria. The compounds and pharmaceutically acceptable salts thereof may be part of a pharmaceutical composition including a pharmaceutically acceptable support.Type: GrantFiled: October 5, 2018Date of Patent: May 19, 2020Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT CURIE, UNIVERSITE DE MONTPELLIERInventors: Jamal Tazi, David Grierson, Florence Mahuteau-Betzer, Pierre Roux
-
Patent number: 10639384Abstract: The present invention relates to novel therapeutic ways for treating Wolfram Syndrome (WS) by targeting the neuronal calcium sensor 1 (NCS1). The present inventors have demonstrated that WFS1, which loss of function is responsible of the Wolfram Syndrome, forms a complex with the neuronal calcium sensor 1 (NCS1). The inventors have further demonstrated that WFS1 associates with NCS1 to prevent its degradation by the proteasome and that NCS1 regulates VDAC expression and mitochondrial respiratory chain. Thus, present invention provides an agonist of NCS1 for use in the treatment of WS. Such an agonist is e.g. a NCS1-encoding polynucleotide, an inhibitor of the proteasome or of calpains. The inventors have further shown that overexpression of NCS1 in WS cells allows increasing complex II driven respiration. The present invention further relates to a method for predicting the severity of WS by measuring the NCS1 level in a sample obtained from a patient.Type: GrantFiled: March 23, 2017Date of Patent: May 5, 2020Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE DE MONTPELLIERInventors: Benjamin Delprat, Cécile Cribaillet-Delettre, Claire Angebault
-
Patent number: 10628944Abstract: The present invention relates generally to the fields of reproductive medicine. More specifically, the present invention relates to methods and devices for determining the quality of an embryo. More specifically, the present invention relates to the use of three dimensional reconstructions for determining the quality of an embryo.Type: GrantFiled: July 1, 2015Date of Patent: April 21, 2020Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), UNIVERSITE DE MONTPELLIER, CENTRE HOSPITALIER UNIVERSITAIRE DE MONPELLIERInventors: Samir Hamamah, Elodie Scalici
-
Patent number: 10603414Abstract: Disclosed is a composition based on copolymers including at least one A-B block copolymer, wherein block A is a polyester and block B is a polyoxyethylene (PEG), and wherein the total molecular mass in weight of the PEG is higher than or equal to 50 kDa, and the ethylene oxide motif/ester motif molar ratio is between 0.5 and 5. The invention also relates to an anti-adhesive material including such a composition, used for the prevention of tissue adhesions and especially for the prevention of intrauterine synechiae.Type: GrantFiled: August 3, 2015Date of Patent: March 31, 2020Assignees: UNIVERSITE DE MONTPELLIER, ECOLE NATIONALE SUPERIEURE DE CHIMIE DE MONTPELLIER, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, CENTRE REGIONAL HOSPITALIER UNIVERSITAIRE DE NIMESInventors: Jean Coudane, Salome Leprince, Xavier Garric, Cedric Paniagua, Stephanie Huberlant, Vincent Letouzey
-
Patent number: 10583114Abstract: The present invention relates to a composition comprising urolithin A, urolithin B, urolithin C, urolithin D, or a combination thereof, for the stimulation of insulin secretion, and to the use of a compound chosen among urolithin A, urolithin B, urolithin C, urolithin D, or a combination thereof, intended for the stimulation of insulin secretion. The present invention also relates to a composition comprising an effective amount of urolithin B, urolithin C, urolithin D, or a combination thereof, for the treatment or the prevention of diabetes mellitus, and in particular for the treatment or the prevention of type 2 diabetes, and to the use of a compound chosen among urolithin B, urolithin C, urolithin D, and a combination thereof, intended for the treatment or the prevention of diabetes mellitus, and in particular of type 2 diabetes.Type: GrantFiled: October 15, 2014Date of Patent: March 10, 2020Assignees: Centre National de la Recherche Scientifique (CNRS), Universite de Montpellier, University of Parma, Ecole Nationale Superieure de Chimie, Centre National de la Recherche Scientifique, Universite de MontpellierInventors: Gerard Cros, Alan Crozier, Margherita Dall'asta, Daniele Del Rio, Richard Magous, Catherine Oiry
-
Publication number: 20200063209Abstract: A method for in vitro predicting of the outcome of an individual having a multiple myeloma, including the steps of: a) measuring the expression level of at least 5 genes and/or proteins encoded by the 5 genes, the genes being selected in a group including NRP2, REEP1, SV2B, ARRB1, CACNA1G, FBLIM1, FGFR1, IRF6, ITGA9, NOVA2, PPP2R2C, SLC5A1, SORL1, SYT7 and THY1, in a biological sample obtained from the individual; b) calculating a score value from the expression level obtained at step a); c) classifying the individual as having a good prognosis status or a bad prognosis status, by comparing the score value obtained at step b) with a reference score value.Type: ApplicationFiled: October 31, 2017Publication date: February 27, 2020Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE DE MONTPELLIERInventors: Jérôme MOREAUX, Laurie HERVIOU, Alboukadel KASSAMBARA, Giacomo CAVALLI
-
Publication number: 20200031925Abstract: The use of differentiation marker CD32 for the detection of cellular reservoirs of a mammalian immunodeficiency virus. Also the use of the differentiation marker CD32 for making a prognosis, diagnosing a remission, and evaluating the efficacy of treatment of the mammalian immunodeficiency. A multi-specific antibody that recognizes both at least one epitope of CD32 and at least one characteristic of the lymphocyte cells, a composition including the antibody, and the use of the antibody in treatment.Type: ApplicationFiled: September 30, 2017Publication date: January 30, 2020Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITÉ DE MONTPELLIERInventors: Monsef BENKIRANE, Gael PETITJEAN, Benjamin DESCOURS
-
Patent number: 10538485Abstract: The present disclosure relates to compound (I) wherein R1 and R2 independently represent a hydrogen atom, a (C1-C4)alkoxy group, a fluoro(C1-C4)alkoxy group, a hydroxyl group, a benzyloxy group, a di(C1-C4)alkylamino group, a pyridyl-vinyl group, a pyrimidinyl-vinyl group, a styryl group, or a —NHCOphenyl group; R3, R4 and R5 independently represent a hydrogen atom, a (C1-C4)alkyl group, a CONHR6 group, a —CONR7R8 group, a —SO2NHR6 group, or a heteroaryl group optionally substituted by a halogen atom, a —(CH2)nNR7R8 group or a hydroxy(C1-C4)alkyl group; R6 represents a hydrogen atom, a —(CHR9)m(CH2)nNR7R8 group or a (C1-C6)alkyl group optionally substituted by a hydroxyl group; or anyone of its pharmaceutically acceptable salt, for use in a method for preventing, inhibiting or treating a disease in a patient suffering thereof, said disease involving a deregulated p53. Some of said compounds are new and also form part of the disclosure.Type: GrantFiled: December 13, 2017Date of Patent: January 21, 2020Assignees: ABIVAX, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT CURIE, UNIVERSITE DE MONTPELLIERInventors: Didier Scherrer, Jamal Tazi, Romain Najman, Florence Mahuteau, Pierre Roux
-
Patent number: 10538617Abstract: Fatty acid polyester derivatives of polyglycosides formed from a polyol having between 2 and 10 hydroxy functions, the 2 hydroxy functions or at least 2 of these hydroxy functions being bound to the anomeric carbon of a reducing carbohydrate that is identical or different for each hydroxy group and selected from the monosaccharides and disaccharides, in which at least one of the other hydroxy groups of the monosaccharide or the disaccharide is esterified by a lipid derivative bearing at least one double bond optionally originating from a vegetable or animal oil, from a mixture of vegetable or animal oils, the double bond or the at least one of the double bonds of the lipid derivative being functionalized by a group selected from the epoxy, amine, alcohol and acid groups, and use thereof in particular in reaction formulations for the production of polymer materials.Type: GrantFiled: July 21, 2015Date of Patent: January 21, 2020Assignees: UNIVERSITE DE MONTPELLIER, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventors: Stéphane Patry, Jean-Pierre Habas
-
Patent number: 10526415Abstract: The invention relates to human anti-Cath-D neutralizing monoclonal antibodies and uses thereof. More particularly, the invention relates to an isolated human monoclonal antibody or a fragment thereof comprising a heavy chain variable region comprising SEQ ID NO: 2 in the H-CDR1 region, SEQ ID NO: 3 in the H-CDR2 region and SEQ ID NO: 4 in the H-CDR3 region; and a light chain variable region comprising SEQ ID NO: 6 in the L-CDR1 region, SEQ ID NO: 7 in the L-CDR2 region and SEQ ID NO: 8 in the L-CDR3 region. The invention also relates to an isolated human monoclonal antibody or a fragment thereof comprising a heavy chain variable region comprising SEQ ID NO: 10 in the H-CDR1 region, SEQ ID NO: 11 in the H-CDR2 region and SEQ ID NO: 12 in the H-CDR3 region; and a light chain variable region comprising SEQ ID NO: 14 in the L-CDR1 region, SEQ ID NO: 15 in the L-CDR2 region and SEQ ID NO: 16 in the L-CDR3 region.Type: GrantFiled: May 20, 2016Date of Patent: January 7, 2020Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), UNIVERSITE DE MONTPELLIER, INSTITUT REGIONAL DU CANCER DE MONTPELLIERInventors: Emmanuelle Liaudet-Coopman, Thierry Chardes, Pierre Martineau, Yahya Ashraf
-
Publication number: 20190390297Abstract: The invention relates to the use, as an extraction agent for extracting at least one rare earth from an aqueous phase including phosphoric acid, of at least one compound of the following general formula (I): where n is an integer equal to 0, 1 or 2, R1 and R2 are H or an aliphatic hydrocarbon group, one of R3 and R4 has the following formula (II): where R5 and R6 are a hydrocarbon, hydroxyl or alkoxyl group, and the other one of R3 and R4 has one of the following formulas (II?) and (III): where R5? and R6? are a hydrocarbon, hydroxyl or alkoxyl group, and R7 and R8 are H or an aliphatic hydrocarbon group. The invention also relates to a method for recovering at least one rare earth using said compound, as well as to specific compounds as such.Type: ApplicationFiled: September 4, 2019Publication date: December 26, 2019Applicants: COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE DE MONTPELLIERInventors: Fanny Mary, Guilhem Arrachart, Stephane Pellet-Rostaing, Antoine Leydier, Veronique Dubois
-
Patent number: 10513534Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 2?-chloro nucleosides according to Formula 2001: or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form or polymorphic form thereof, wherein B, Z and PD are as described herein.Type: GrantFiled: October 7, 2013Date of Patent: December 24, 2019Assignees: IDENIX PHARMACEUTICALS LLC, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE DE MONTPELLIERInventors: Gilles Gosselin, Christophe Claude Parsy, Francois-Rene Alexandre, Houcine Rahali, Jean-Francois Griffon, Dominique Surleraux, Cyril B. Dousson, Claire Pierra, Adel M. Moussa, Benjamin Alexander Mayes, Alistair James Stewart
-
Publication number: 20190382347Abstract: The present disclosure relates to the use of a compound of formula (I) or anyone of its pharmaceutically acceptable salts, in the treatment and/or prevention of an inflammatory disease; wherein: means an aromatic ring wherein V is C or N and when V is N; Q is N or O, provided that R? does not exist when Q is O; R? independently represent a hydrogen atom or a group chosen among a (C1-C3)alkyl group, a halogen atom, a hydroxyl group, a —COOR1 group, a —NO2 group, a —NR1R2 group, a morpholinyl or a morpholino group, a N-methylpiperazinyl group, a (C1-C3)fluoroalkyl group, a —O—P(?O)—(OR3)(OR4) group, a (C1-C4)alkoxy group and a —CN group, and can further be a group chosen among:Type: ApplicationFiled: August 29, 2019Publication date: December 19, 2019Applicants: ABIVAX, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT CURIE, UNIVERSITE DE MONTPELLIERInventors: Didier SCHERRER, Jamal TAZI, Florence MAHUTEAU, Romain NAJMAN
-
Publication number: 20190367670Abstract: The present invention relates to new biopolymer, i.e. bioorganic nylons incorporating peptidic blocks obtained by a process of polymerization of amino peptidic blocks. The process of the invention comprises the steps of mixing amino peptidic blocks with or without a diaminoalcane and reacting the mixture according to polycondensation with a diacyl chloride in homogeneous or heterogeneous media.Type: ApplicationFiled: December 9, 2016Publication date: December 5, 2019Applicants: Universite De Montpellier, Centre National de la Recherche Scientifique (CNRS)Inventors: Jean Martinez, Ahmad Mehdi, Gilles Subra, Saïd Jebors
-
Patent number: 10483720Abstract: A laser device is provided for generating a helical-shaped optical wave and includes: (i) a gain region located between one first end defined by a first mirror and a second end defined by an exit region, (ii) a second mirror arranged so as to form with the first mirror an optical cavity including the gain region and a gap between the exit region and the second mirror, (iii) apparatus for pumping the gain region so as to generate the optical wave, wherein the laser device further includes at least one apparatus for shaping the light intensity and/or phase profiles of the optical wave and arranged for selecting at least one rotary-symmetrical transverse mode of the optical wave, the rotary-symmetrical transverse mode being chosen between those with a radial index equal to zero and with an azimuthal index being an integer with a module higher or equal to 1.Type: GrantFiled: December 15, 2015Date of Patent: November 19, 2019Assignees: UNIVERSITE DE MONTPELLIER, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventors: Arnaud Garnache-Creuillot, Mikhael Myara, Isabelle Sagnes, Luc Le Gratiet, Mohammed Sellahi, Mohammed Seghilani, Philippe Lalanne
-
Publication number: 20190322656Abstract: The manufacture of 8-chloro-N-[4-(trifluoromethoxy)phenyl]quinolin-2-amine, or a pharmaceutically acceptable salt thereof, and use of 8-chloro-N-[4-(trifluoromethoxy)phenyl]quinolin-2-amine, or a pharmaceutically acceptable salt thereof, for treating various conditions, and/or inhibiting replication of HIV-1 in a patient infected with HIV-1, by administering to a patient in need thereof an effective quantity of 8-chloro-N-[4-(trifluoromethoxy)phenyl]quinolin-2-amine, or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: July 3, 2019Publication date: October 24, 2019Applicants: ABIVAX, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT CURIE, UNIVERSITE DE MONTPELLIERInventors: Florence MAHUTEAU, Romain NAJMAN, Jamal TAZI
-
Patent number: 10450629Abstract: The invention relates to the use, as an extraction agent for extracting at least one rare earth from an aqueous phase including phosphoric acid, of at least one compound of the following general formula (I): where n is an integer equal to 0, 1 or 2, R1 and R2 are H or an aliphatic hydrocarbon group, one of R3 and R4 has the following formula (II): where R5 and R6 are a hydrocarbon, hydroxyl or alkoxyl group, and the other one of R3 and R4 has one of the following formulas (II?) and (III): where R5? and R6? are a hydrocarbon, hydroxyl or alkoxyl group, and R7 and R8 are H or an aliphatic hydrocarbon group. The invention also relates to a method for recovering at least one rare earth using said compound, as well as to specific compounds as such.Type: GrantFiled: May 3, 2016Date of Patent: October 22, 2019Assignees: COMMISSARIAT A L+ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE DE MONTPELLIERInventors: Fanny Mary, Guilhem Arrachart, Stephane Pellet-Rostaing, Antoine Leydier, Veronique Dubois
-
Publication number: 20190316223Abstract: The present invention is in the field of surfactants to extract a platinum group metal or gold, in particular palladium, from organic compositions. In particular, the invention concerns the use of surfactants to back-extract a platinum group metal or gold, in particular palladium, from organic compositions further comprising an extractant of said platinum group metal or gold, in particular palladium from an aqueous solution.Type: ApplicationFiled: May 19, 2017Publication date: October 17, 2019Applicants: Centre National de la Recherche Scientifique, Universite d'Avignon et des Pays de Vaucluse, Universite de Strasbourg, Commissariat a l'Energie Atomique et aux Energies Alternatives, Ecole Nationale Superieure de Chimie de Montpellier, Universite de MontpellierInventors: Frédéric Jean-Jacques Bihel, Damien Bourgeois, Stéphane Desgranges, Daniel Meyer, Christiane Contino-Pepin, Martine Schmitt, Patrick Hervé Denis Wagner
-
Publication number: 20190310191Abstract: The invention relates to a device (1) for detecting the presence of determined molecules, comprising, one on top of the other: a first substrate layer (11), a second reflection layer (12), and a third dielectric layer (13). The invention is characterised by an antenna array (14) with conductive parts (143), repeating in one direction (D, D2), the network (14) forming a plasmonic resonator (140) that can be brought into contact with the molecules and arranged so as to emit at least one thermal radiation peak corresponding to at least one characteristic mode of thermal vibration of the determined molecules.Type: ApplicationFiled: October 23, 2017Publication date: October 10, 2019Applicants: Universite De Montpellier, Centre National de la Recherche Scientifique (CNRS)Inventors: Thierry Taliercio, Laurent Cerutti